“It’s designed to be simple in a way, even though it’s an incredibly complex device”, Distalmotion CEO Greg Roche explains to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Roche sits down with BI analyst Matt Henriksson for an in-depth interview on the company, how its Dexter Robotic Surgery System and single-use instrument platform differentiates itself from others in the robotic market and how it can shorten the learning curve that can increase adoption of robots in ambulatory surgical centers.

&ldquo;It&rsquo;s designed to be simple in a way, even though it&rsquo;s an incredibly complex device&rdquo;, Distalmotion CEO Greg Roche explains to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Roche sits down with BI analyst Matt Henriksson for an in-depth interview on the company, how its Dexter Robotic Surgery System and single-use instrument platform differentiates itself from others in the robotic market and how it can shorten the learning curve that can increase adoption of robots in ambulatory surgical centers.

Vanguards of Healthcare is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.

Vanguards of Healthcare is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.

Vanguards of Healthcare by Bloomberg Intelligence

Distalmotion’s Approach to Spread Surgical Robots to More

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/005146c4-089f-4e4e-983a-b46d010d541a/transcript

“Neuroscience is what oncology was 20 years ago,” says Cristian Massacesi, Chief Medical Officer and Head of Development at Bristol Myers Squibb. Massacesi joins Bloomberg Intelligence pharmaceuticals analyst Sam Fazeli to discuss Bristol Myers’ push into neuroscience, including Alzheimer’s therapies aimed at tau, a protein tied to brain tangles in the disease. They also explore the company’s oncology pipeline, including PD-L1/VEGF bispecifics, next-generation antibody-drug conjugates and advances in multiple myeloma. Massacesi explains how Bristol is balancing internal innovation with external partnerships and why AI could fundamentally change the economics and success rates of drug development.

&ldquo;Neuroscience is what oncology was 20 years ago,&rdquo; says Cristian Massacesi, Chief Medical Officer and Head of Development at Bristol Myers Squibb. Massacesi joins Bloomberg Intelligence pharmaceuticals analyst Sam Fazeli to discuss Bristol Myers&rsquo; push into neuroscience, including Alzheimer&rsquo;s therapies aimed at tau, a protein tied to brain tangles in the disease. They also explore the company&rsquo;s oncology pipeline, including PD-L1/VEGF bispecifics, next-generation antibody-drug conjugates and advances in multiple myeloma. Massacesi explains how Bristol is balancing internal innovation with external partnerships and why AI could fundamentally change the economics and success rates of drug development.

Bristol Myers on Why Neuroscience Could Be the Next Oncology

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/aaac00fd-b6f1-49c9-ba19-b46b00cb4332/transcript

“If you plan, the cases can go much more smoothly. And if you have patient-specific instrumentation, they can go much more quickly” says restor3D’s CEO Kurt Jacobus in this episode of Vanguards of Healthcare. He sat down with BI analyst Matt Henriksson to elaborate on personalized orthopedic implants, outlining how the win then for the surgeon is the capacity to complete more cases, with better patient outcomes reputationally, and the win for the facility is getting another case into the operating room. 

The in-depth interview covered restor3D’s AI planning and 3D printing capabilities, its path in integrating the Conformis acquisition to allow it to compete against larger companies in the knee-replacement market and the upcoming launch of its patient app. He also discussed how his drive to use technology to solve problems led him from the consulting world to leading medtech companies.

Listen to this episode on Apple Podcasts and Spotify.

 

&ldquo;If you plan, the cases can go much more smoothly. And if you have patient-specific instrumentation, they can go much more quickly&rdquo; says restor3D&rsquo;s CEO Kurt Jacobus in this episode of Vanguards of Healthcare. He sat down with BI analyst Matt Henriksson to elaborate on personalized orthopedic implants, outlining how the win then for the surgeon is the capacity to complete more cases, with better patient outcomes reputationally, and the win for the facility is getting another case into the operating room.&nbsp;
The in-depth interview covered restor3D&rsquo;s AI planning and 3D printing capabilities, its path in integrating the Conformis acquisition to allow it to compete against larger companies in the knee-replacement market and the upcoming launch of its patient app. He also discussed how his drive to use technology to solve problems led him from the consulting world to leading medtech companies.
Listen to this episode on Apple Podcasts and Spotify.
&nbsp;

Restor3D Combines AI with 3D Printing to Create Personalized Ortho Solutions

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/3c93757f-71f8-4b41-8406-b46600c1e294/transcript

“I think it’s the most exciting period in cancer discovery and development that I’ve experienced over the last 25 years,” says Susan Galbraith, executive vice president of oncology R&D at AstraZeneca. Galbraith joins Bloomberg Intelligence analyst Sam Fazeli fresh from the ASCO conference to unpack how ctDNA, earlier intervention and next-generation oncology platforms could reshape cancer care. They discuss AstraZeneca’s Stride regimen in liver cancer, Serena-6 in breast cancer, progress in pancreatic cancer and the company’s push across ADCs, bispecifics, CAR-T and radio conjugates.

&ldquo;I think it&rsquo;s the most exciting period in cancer discovery and development that I&rsquo;ve experienced over the last 25 years,&rdquo; says Susan Galbraith, executive vice president of oncology R&amp;D at AstraZeneca. Galbraith joins Bloomberg Intelligence analyst Sam Fazeli fresh from the ASCO conference to unpack how ctDNA, earlier intervention and next-generation oncology platforms could reshape cancer care. They discuss AstraZeneca&rsquo;s Stride regimen in liver cancer, Serena-6 in breast cancer, progress in pancreatic cancer and the company&rsquo;s push across ADCs, bispecifics, CAR-T and radio conjugates.

AstraZeneca’s ASCO Readout on Oncology’s Next Wave

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/70f50f64-3628-4245-985d-b46400d36ead/transcript

Distalmotion’s Approach to Spread Surgical Robots to More

In 1 playlist(s)

Vanguards of Healthcare by Bloomberg Intelligence

Social links

Follow podcast

Recent clips